TY - CHAP M1 - Book, Section TI - Pharmacology and Toxicity of Antineoplastic Drugs A1 - Lichtman, Marshall A. A1 - Kaushansky, Kenneth A1 - Prchal, Josef T. A1 - Levi, Marcel M. A1 - Burns, Linda J. A1 - Linch, David C. PY - 2022 T2 - Williams Manual of Hematology, 10e AB - Knowledge of drug actions, clinical toxicities, pharmacokinetics, and interactions is essential for the safe and effective administration of chemotherapy.Treatment should be based on clinical trials that define optimal doses, schedule, and drug combinations.Choice of treatment should depend on the tumor stage and histology with consideration of individual patient tolerance.Drug approval by regulatory authorities and availability differ by countries.High-dose conditioning regimens used in hematopoietic cell transplantation (HCT) result in additional organ toxicities not seen at conventional doses.Chemotherapy often targets the process of DNA replication. More recently, drugs have been introduced to target specific cellular processes, including receptor signaling, inhibition of oncoproteins, angiogenesis, and membrane cluster of differentiation antigens.Dose modification may be needed for patients with renal or hepatic dysfunction depending on the major route of drug clearance (Table 38–1). SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - hemonc.mhmedical.com/content.aspx?aid=1189334234 ER -